M

Mankind Pharma Ltd
NSE:MANKIND

Watchlist Manager
Mankind Pharma Ltd
NSE:MANKIND
Watchlist
Price: 2 910.6 INR -2.93% Market Closed
Market Cap: 1.2T INR
Have any thoughts about
Mankind Pharma Ltd?
Write Note

Mankind Pharma Ltd
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Mankind Pharma Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
M
Mankind Pharma Ltd
NSE:MANKIND
Note Receivable
â‚ą1.5B
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Note Receivable
â‚ą2.3B
CAGR 3-Years
-11%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Note Receivable
â‚ą3.3B
CAGR 3-Years
1 392%
CAGR 5-Years
45%
CAGR 10-Years
0%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Note Receivable
â‚ą10.9B
CAGR 3-Years
-35%
CAGR 5-Years
-18%
CAGR 10-Years
-2%
Lupin Ltd
NSE:LUPIN
Note Receivable
â‚ą2.7B
CAGR 3-Years
-28%
CAGR 5-Years
-2%
CAGR 10-Years
-2%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Note Receivable
â‚ą2.3B
CAGR 3-Years
87%
CAGR 5-Years
18%
CAGR 10-Years
7%
No Stocks Found

Mankind Pharma Ltd
Glance View

Market Cap
1.2T INR
Industry
Pharmaceuticals

Mankind Pharma Ltd. has carved a unique niche in the pharmaceutical landscape of India, emerging as a formidable entity through an intriguing blend of affordability and accessibility. Founded in 1995 by R. C. Juneja, the company has steadily grown its portfolio to encompass a vast range of pharmaceutical products spanning prescription medications, over-the-counter (OTC) drugs, and consumer healthcare goods. Operating with a distinctive business model rooted in the ethos of delivering quality medicine at affordable prices, Mankind Pharma reaches deep into the densely populated tier II and tier III cities of India, ensuring that healthcare is accessible to the masses who need it the most. This strategic outreach, coupled with strong marketing and distribution networks, serves as a cornerstone of its business success. The company’s financial health is buoyed by its diversified product range, which caters to multiple therapeutic areas including antibiotics, cardiovascular, antifungal, and gastrointestinal, among others. Their robust R&D initiatives further reinforce their competitive edge, enabling them to continually introduce new and effective products that resonate with both healthcare providers and consumers. Revenue streams are not just confined to domestic borders; Mankind Pharma has been expanding its footprint internationally, penetrating markets across Asia, Africa, and the Americas. By striking a strategic balance between volume-driven pricing models and extensive market reach, Mankind Pharma not only emphasizes profitability but also solidifies its commitment to public health initiatives globally, thus creating a sustainable and progressive business trajectory.

MANKIND Intrinsic Value
1 393.58 INR
Overvaluation 52%
Intrinsic Value
Price
M

See Also

What is Mankind Pharma Ltd's Note Receivable?
Note Receivable
1.5B INR

Based on the financial report for Mar 31, 2024, Mankind Pharma Ltd's Note Receivable amounts to 1.5B INR.

What is Mankind Pharma Ltd's Note Receivable growth rate?
Note Receivable CAGR 3Y
0%

Over the last year, the Note Receivable growth was -16%.

Back to Top